AI Article Synopsis
- Hepatocellular carcinoma (HCC) is a common cancer with a need for effective prognostic biomarkers, and this study investigates α-methylacyl-CoA racemase (AMACR) as a potential candidate.
- A cohort of 158 HCC patients was analyzed using tissue microarrays to correlate AMACR expression with key clinical parameters and patient survival.
- Findings show that low AMACR expression is linked to poor survival and various adverse clinical markers, suggesting AMACR could serve as a prognostic indicator for early recurrence and metastasis of HCC post-surgery.
Article Abstract
Aims: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, and it is still lacking effective prognostic biomarkers so far. Previous results of the iTRAQ-based quantitative proteomics study (iTRAQ-2DLC-MS/MS) have shown that α-methylacyl-CoA racemase (AMACR) might be a promising prognostic biomarker for the early recurrence/metastasis of hepatocellular carcinoma (HCC). Here a large-scale cohort clinical study was performed to evaluate its prognostic potential.
Methods: HCC samples from patients (n=158) were used for the construction of tissue microarray. The expression level of AMACR was determined by immunohistochemical staining. A large-scale cohort clinical study between the expression of AMACR and some major clinical parameter has been performed to assess the prognostic potential of AMACR for the early recurrence/metastasis of HCC.
Results: Some important clinical parameters such as α-fetoprotein, tumour numbers, dissemination to regional lymph nodes, tumour capsule and portal vein tumour thrombosis are significantly associated with the low expression of AMACR. The expression of AMACR was an independent factor for the survival of patients with HCC. The median survival time was 17 months in the low-expression group compared with 45 months in the high-expression group.
Conclusions: This study reveals that the AMACR might be a potential prognostic marker for predicting early recurrence/metastasis of HCC after hepatectomy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215266 | PMC |
| http://dx.doi.org/10.1136/jclinpath-2014-202378 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characteristics and survival outcomes in pediatric patients with spinal chordomas: insights from the National Cancer Database and review of the literature.
J Neurooncol
January 2025
Departments of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Purpose: Spinal chordomas are aggressive tumors that rarely occur in the pediatric population. Demographics and post-treatment outcomes in this select group of patients is poorly studied. We hence aimed to analyze the clinical characteristics, demographics, and survival outcomes of pediatric patients with spinal chordomas, in contrast to the adult population.
View Article and Find Full Text PDFTherapeutic Landscape of FOXM1 in Triple-Negative Breast Cancer and Aggressive Solid Cancers.
Cancers (Basel)
November 2024
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USA.
Triple-negative breast cancer (TNBC) is one of the most aggressive forms of breast cancer, lacking common treatment targets such as estrogen (ER), progesterone (PR), and HER2 receptors. This subtype is associated with significant heterogeneity, chemoresistance, early recurrence, metastasis, and poor patient survival. FOXM1 is a cancer-promoting transcription factor that plays a critical role in TNBC and other highly aggressive cancers by driving cell proliferation, invasion, metastasis, and drug resistance.
View Article and Find Full Text PDFDrainless Uniportal VATS Wedge Resection for Early Non-Small Cell Lung Cancer: Propensity Analysis of the Effect of Polyglycolic Acid Sheet (Neoveil).
Diagnostics (Basel)
November 2024
Division of Thoracic Surgery, Department of Surgery, College of Medicine, National Taiwan University Hospital and National Taiwan University, Taipei 100, Taiwan.
Absorbable biomaterials as adjuvant therapy after thoracoscopy are sometimes used in clinical scenarios. With the prevalence of enhanced rapid recovery in thoracic surgery, drainless video-assisted thoracoscopy surgery (VATS) is often adopted by thoracic surgeons. Here, we discuss utilizing an absorbable biomaterial, Neoveil (Polyglycolic Acid sheet), for drainless VATS to treat early lung cancer.
View Article and Find Full Text PDFFerroptosis: insight into the treatment of hepatocellular carcinoma.
Cancer Cell Int
November 2024
Department of Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, China.
Hepatocellular carcinoma (HCC) is one of the most common malignances in the world, with high morbidity and mortality. Due to the hidden onset of symptoms, there are huge obstacles in early diagnosis, recurrence, metastasis and drug resistance. Although great strides have been made in the treatment of HCC, effective treatment options are still limited and achieving longer survival for patients remains urgent.
View Article and Find Full Text PDFApplication and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.
Am J Cancer Res
September 2024
Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University Chongqing 400038, China.
HER2-positive breast cancer is highly aggressive, with a significant risk of recurrence and metastasis, leading to a poor prognosis. While most early-stage HER2-positive breast cancer patients benefit from combining trastuzumab monoclonal antibody with chemotherapy, the therapeutic response to various drug combinations varies across the HER2+ patient population. Therefore, predicting the prognosis and treatment response of HER2+ breast cancer patients to specific regimens is crucial for selecting appropriate precision individualized therapies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!